Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 226 to 240 of 2581 results for methods

  1. Communication:- What are the most clinically effective and cost-effective methods of addressing patient and carer concerns about strong opioids, including anticipating and managing adverse effects, and engaging patients in prescribing decisions?

    Communication:- What are the most clinically effective and cost-effective methods of addressing patient and carer concerns about strong...

  2. Promoting a shift to zero- and low-emission travel:- What methods are effective and cost effective at promoting a shift to zero- and low-emission modes of travel, including active travel?

    Question Promoting a shift to zero- and low-emission travel:- What methods are effective and cost effective at promoting a shift to...

  3. Ectopic pregnancy and miscarriage (QS69)

    This quality standard covers the diagnosis and initial management of ectopic pregnancy and miscarriage in women in their first trimester (up to 13 completed weeks of pregnancy). It includes assessment and diagnosis for women with suspected early pregnancy loss. It describes high-quality care in priority areas for improvement.

  4. Osteoporosis (QS149)

    This quality standard covers managing osteoporosis in adults (aged 18 and over), including assessing risk and preventing fragility fractures. It describes high-quality care in priority areas for improvement.

  5. Interventional procedures programme manual (PMG28)

    This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual

  6. Oral health promotion: general dental practice (NG30)

    This guideline covers how general dental practice teams can convey advice about oral hygiene and the use of fluoride. It also covers diet, smoking, smokeless tobacco and alcohol intake.

  7. Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

    Awaiting development Reference number: GID-TA10773 Expected publication date: TBC

  8. Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

    Awaiting development Reference number: GID-TA10604 Expected publication date: TBC

  9. Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]

    Awaiting development Reference number: GID-TA10776 Expected publication date: TBC

  10. Timrepigene emparvovec for treating choroideremia [ID3916]

    Awaiting development Reference number: GID-TA10787 Expected publication date: TBC

  11. Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]

    Awaiting development Reference number: GID-TA10823 Expected publication date: TBC

  12. Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]

    Awaiting development Reference number: GID-TA10867 Expected publication date: TBC

  13. Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]

    Awaiting development Reference number: GID-TA10896 Expected publication date: TBC

  14. Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

    Awaiting development Reference number: GID-TA10683 Expected publication date: TBC

  15. Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

    Awaiting development Reference number: GID-TA10684 Expected publication date: TBC